Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Minerva Endocrinologica 2018 December;43(4) > Minerva Endocrinologica 2018 December;43(4):511-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Endocrinologica 2018 December;43(4):511-6

DOI: 10.23736/S0391-1977.17.02551-2

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Comparison of curative effect of 131I and antithyroid drugs in Graves’ disease: a meta-analysis

Ju YUAN 1, Xiuqing LU 2 , Yan YUE 1

1 Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou, China; 2 Department of Neurology, Henan Province Hospital of TCM, Zhengzhou, China


PDF


INTRODUCTION: Radioactive 131I is currently reported to be a potential effective intervention for Graves’ disease treatment in China. Whether 131I treatment was associated with effective outcome or reduced risk of side effects, recurrence rate remained unknown.
EVIDENCE ACQUISITION: Eligible studies were selected from Chinese VIP, Wangfang, CNKI databases using the keywords “Iodine” and “Graves’ disease”. Finally, 13 clinical trials met the inclusion criterion and were included this meta-analysis.
EVIDENCE SYNTHESIS: Our meta-analysis included 1355 patients diagnosed of Graves’ disease with regular anti-thyroid drugs oral administration and 1320 patients with 131I therapy. The results showed that there was significant symptom improvement with radioactive iodine intervention (Odd Ratio [OR]=4.50, 95% CI: 3.55-5.71, P<0.01). Three studies mentioned side effects, 6 mentioned recurrence rate and another 6 mentioned hypothyroidism. The ORs and 95% CIs for these subgroups were 0.12 (0.06, 0.21), 0.08 (0.05, 0.13) and 2.27 (1.77, 2.92) respectively. It means a significant reduction of side effects and recurrence rate but increased hypothyroidism after 131I intervention in Graves’ disease.
CONCLUSIONS: Treatment with 131I was associated with better clinical outcome; it reduced side effects and reccurence rate but increased hypothyroidism in Graves’ disease.


KEY WORDS: Antithyroid agents - Graves’ disease - Meta-analysis

inizio pagina